Companies Anika Therapeutics, Inc.

Anika Therapeutics (ANIK): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Anika Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$2,033,370CEO Stephen Griffin · source

Say-on-pay support88.32%Latest vote · source

CEO vs. named peers6th pct.Of 16 peer CEOs

CEO pay ratio44:1To the median employee

CEO pay, last three years

$2,646,150FY2024
$2,033,370FY2025

CEO total pay was $2,033,370 in fiscal 2025, down from $2,646,150 in fiscal 2024.

FY2025: salary $500,000 · bonus $300,000 · stock awards $1,215,222 · option awards $0

Executives and directors

Anne Nunes · COO Cheryl Blanchard · Executive Ian McLeod · Executive Stephen Griffin · CEO David Colleran · General Counsel Gary P. Fischetti · Independent Director Glenn R. Larsen, Ph.D · Independent Director John B. Henneman, III · Lead Independent Director Joseph H. Capper · Independent Director Sheryl L. Conley · Independent Director Stephen O. Richard · Independent Director Susan L. N. Vogt · Former director (through FY2025)William R. Jellison · Independent Director

Frequently asked questions

Who was the highest-paid executive at Anika Therapeutics, Inc. in fiscal 2025?

As disclosed, Cheryl Blanchard (Executive Chair; Former President and Chief Executive Officer) was the highest-paid executive at Anika Therapeutics, Inc. in fiscal 2025, with total compensation of $4,887,318.

How does Anika Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?

As disclosed, Stephen Griffin's total compensation ranked at the 6th percentile of Anika Therapeutics, Inc.'s disclosed peer group.

What is Anika Therapeutics, Inc.'s CEO-to-median employee pay ratio?

As disclosed, Anika Therapeutics, Inc.'s CEO-to-median employee pay ratio was 44:1.

How did shareholders vote on Anika Therapeutics, Inc.'s executive compensation?

As disclosed, 88.32% of shareholders supported Anika Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.

How much does Anika Therapeutics, Inc. spend in total on board compensation for fiscal 2025?

As disclosed, Anika Therapeutics, Inc. reported total board compensation of $1,824,976 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Cheryl Blanchard	$750,397	$638,000	$3,476,669	$0	$0	$0	$22,252	$4,887,318
Executive Chair; Former President and Chief Executive Officer
Stephen Griffin	500,000	300,000	1,215,222	0	0	0	18,148	2,033,370
President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer
David Colleran	486,424	219,000	889,624	0	0	0	19,157	1,614,205
Executive Vice President, General Counsel and Secretary
Anne Nunes	157,639	0	505,922	0	0	0	282,310	946,571
Former Senior Vice President, Chief Operations Officer
Ian McLeod	345,362	121,987	275,943	0	0	0	22,252	765,544
Senior Vice President, Chief Accounting Officer and Treasurer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Cheryl Blanchard	$4,887,318	$5,103,466	$4,459,800	↓ −216,148
Stephen Griffin	2,033,370	2,646,150	—	↓ −612,780
David Colleran	1,614,205	1,668,587	1,550,514	↓ −54,382
Anne Nunes	946,571	1,131,633	1,013,585	↓ −185,062
Ian McLeod	765,544	—	—	—

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

We have designed our compensation program to: Motivate and reward our executives to achieve or exceed our financial and operating performance objectives; Propel our business forward through a focus on operational excellence and execution of our business strategy; Link each NEO's compensation with specific business objectives; Align each NEO's compensation with the interests of long-term stockholders by tying a significant portion of total compensation opportunity to the value of our stock; Reinforce accountability and cooperation by tying a significant portion of total NEO compensation to overall Company performance; Attract and retain talented leaders who can drive and implement our growth and operational excellence strategies; Reward individual performance and accomplishments; Keep the compensation packages competitive with those of our peers and other companies with whom we compete for highly-skilled top talent

CEO STI target (% of salary)	85%
CEO LTI target (% of salary)	—
Independent consultant	Willis Towers Watson
Clawback policy	True
Anti-hedging	True
Anti-pledging	True

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Ian McLeod	RSU	2025-03-14	—	—	17,344	—	$275,943
Anne Nunes	RSU	2025-03-14	—	—	31,799	—	505,922
Cheryl Blanchard	RSU	2025-03-14	—	—	218,521	—	3,476,669
David Colleran	RSU	2025-03-14	—	—	55,916	—	889,624
Stephen Griffin	RSU	2025-03-14	—	—	76,381	—	1,215,222

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Ian McLeod	$275,943	$0	$0	0.0%
Anne Nunes	505,922	0	0	0.0%
Cheryl Blanchard	3,476,669	0	0	0.0%
David Colleran	889,624	0	0	0.0%
Stephen Griffin	1,215,222	0	0	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Ian McLeod	RSU	2,536	—	$24,371
Ian McLeod	RSU	3,173	—	30,493
Ian McLeod	RSU	3,484	—	33,481
Ian McLeod	RSU	11,324	—	108,824
David Colleran	RSU	13,669	—	131,359
David Colleran	RSU	14,082	—	135,328
David Colleran	RSU	15,625	—	150,156
Stephen Griffin	RSU	18,672	—	179,438
Stephen Griffin	RSU	19,236	—	184,858
David Colleran	RSU	28,165	—	270,666
Stephen Griffin	RSU	32,175	—	309,202
Stephen Griffin	RSU	38,473	—	369,726
Cheryl Blanchard	RSU	60,900	—	585,249
Cheryl Blanchard	RSU	71,403	—	686,183
Cheryl Blanchard	RSU	73,559	—	706,902

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
John B. Henneman, IIIIndependent · Lead Independent Director · Governance and Nominating	$117,500	$149,997	$0	$0	$0	$267,497
Susan L. N. VogtIndependent · Departed during FY	80,000	149,997	0	0	0	229,997
Stephen O. RichardIndependent · Audit (Chair) · Governance and Nominating	80,000	149,997	0	0	0	229,997
Sheryl L. ConleyIndependent · Audit · Compensation (Chair)	75,000	149,997	0	0	0	224,997
William R. JellisonIndependent · Audit · Not standing for re-election	75,000	149,997	0	0	0	224,997
Joseph H. CapperIndependent · Compensation	72,500	149,997	0	0	0	222,497
Glenn R. Larsen, Ph.DIndependent · Compensation · Not standing for re-election	62,500	149,997	0	0	0	212,497
Gary P. FischettiIndependent · Compensation	62,500	149,997	0	0	0	212,497
Cheryl R. Blanchard, Ph.DEmployee director · Board Chair	0	0	0	—	0	0
Stephen D. GriffinEmployee director · Newly elected	0	0	0	—	0	0

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$149,997
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	20,000 / 15,000 / 10,000
Stock ownership guideline	3x annual Board retainer (directors); 3x base salary (CEO); 1x base salary (other NEOs)

Total cost of the board

Component	FY2025
Cash retainers and fees	$625,000
Equity awards (grant-date value)	$1,199,976
All other compensation	$0
Total cost of the board	$1,824,976

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Anika Therapeutics as a peer

Companies that benchmark against ANIK

7 companies name ANIK as a compensation peer

Each company listed discloses ANIK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ANIK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

KPTI Karyopharm Therapeutics, Inc.CDMO Avid Bioservices, Inc.MDXG MiMedx Group, Inc.AKBA Akebia Therapeutics, Inc.AORT Artivion, Inc.COLL Collegium Pharmaceutical, Inc.AXGN AxoGen, Inc.HRTX Heron Therapeutics, Inc.SRDX SurModics, Inc.MGNX MacroGenics, Inc.ORGO Organogenesis Holdings Inc.RIGL Rigel Pharmaceuticals, Inc.TVTX Travere Therapeutics, Inc.VNDA Vanda Pharmaceuticals, Inc.VCEL Vericel CorporationBVS Bioventus Inc.

Peer reciprocity

The companies Anika Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.

MiMedx Group, Inc. (MDXG)⁵⁷SurModics, Inc. (SRDX)⁵⁸Organogenesis Holdings Inc. (ORGO)⁵⁹

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Vericel Corporation	2025	Dominick Colangelo	$860,000	$3,964,630	$5,456,287	$860,000	$11,156,368
2	AxoGen, Inc.	2025	Michael Dale	775,865	7,342,895	0	906,133	9,047,454
3	Travere Therapeutics, Inc.	2025	Eric Dube	854,250	3,314,520	3,309,384	964,125	8,457,151
4	MiMedx Group, Inc.	2025	Joseph Capper	768,173	4,699,000	819,422	887,800	7,182,208
5	Artivion, Inc.	2025	J. Patrick Mackin	835,145	5,006,990	0	991,368	6,883,108
6	Organogenesis Holdings Inc.	2025	Gary Gillheeney	979,105	2,833,330	1,380,017	1,536,575	6,811,754
7	Akebia Therapeutics, Inc.	2025	John Butler	864,010	2,164,338	2,024,798	580,973	5,652,339
8	Rigel Pharmaceuticals, Inc.	2025	Raul Rodriguez	787,405	951,327	2,241,570	634,649	4,658,805
9	Avid Bioservices, Inc.	2024	Nicholas Green	650,000	3,776,336	0	0	4,475,343
10	Bioventus Inc.	2025	Robert Claypoole	824,110	1,982,530	662,949	781,256	4,299,108
11	Vanda Pharmaceuticals, Inc.	2025	Mihael Polymeropoulos	965,655	2,007,000	0	834,326	3,851,468
12	SurModics, Inc.	2024	Gary Maharaj	647,481	940,000	1,410,000	654,215	3,665,496
13	Heron Therapeutics, Inc.	2025	Craig Collard	689,431	946,254	1,352,917	517,189	3,516,291
14	Karyopharm Therapeutics, Inc.	2025	Richard Paulson	770,000	838,996	241,544	350,350	2,320,902
15	MacroGenics, Inc.	2025	Eric Risser	561,568	52,000	1,049,386	251,900	2,078,854
16	Anika Therapeutics, Inc.	2025	Stephen Griffin	500,000	1,215,222	0	0	2,033,370
17	Collegium Pharmaceutical, Inc.	2025	Vikram Karnani	875,000	0	0	835,406	1,715,846

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Anika Therapeutics, Inc.	100%	PSU 67 · RSU 33	No	Willis Towers Watson
Akebia Therapeutics, Inc.	90%	Options 50 · RSU 25 · MSU 25	No	Pearl Meyer
Artivion, Inc.	118.7%	PSU 50 · RSU 50	No	Willis Towers Watson
Avid Bioservices, Inc.	0%	RSU 50 · PSU 50	No	Anderson Pay Advisors, LLC
AxoGen, Inc.	116.79%	PSU 50 · RSU 50	No	Aon
Bioventus Inc.	not disclosed	RSU 49 · PSU 26 · Options 25	No	Aon plc
Collegium Pharmaceutical, Inc.	127.3%	RSU 70 · PSU 30	Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index	Alpine Rewards, LLC
Heron Therapeutics, Inc.	not disclosed	Option 66.67 · RSU 33.33	not disclosed	Compensia, Inc.
Karyopharm Therapeutics, Inc.	90%	not disclosed	Yes — Relative TSR	Alpine, WTW
MacroGenics, Inc.	85%	not disclosed	not disclosed	Alpine Rewards, LLC
MiMedx Group, Inc.	115%	not disclosed	No	Willis Towers Watson
Organogenesis Holdings Inc.	not disclosed	not disclosed	not disclosed	Pearl Meyer
Rigel Pharmaceuticals, Inc.	124%	Options 75 · RSU 25	No	Pearl Meyer
SurModics, Inc.	126.3%	Option 60 · Restricted Shares 40	not disclosed	Pay Governance LLC
Travere Therapeutics, Inc.	150%	not disclosed	No	Aon
Vanda Pharmaceuticals, Inc.	108%	not disclosed	Yes — Relative TSR	Willis Towers Watson
Vericel Corporation	100%	Options 58 · RSU 42	not disclosed	FW Cook

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-06-18	8,268,676	1,093,946	31,179	88.32%	Passed
2025	2025-06-20	8,374,076	2,529,081	41,849	76.8%	Passed
2024	2024-07-09	11,020,273	129,717	6,748	98.84%	Passed
2023	2023-06-14	11,873,054	227,519	51,162	98.12%	Passed
2022	2022-06-08	12,145,089	286,360	54,847	97.7%	Passed
2021	2021-06-16	9,121,886	2,705,453	21,311	77.13%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-06-18	88.32%^a
2025	2025-06-20	76.8%^b
2024	2024-07-09	98.84%^c

a. Approved under the standard stated in the filing — “Abstentions will not count as votes cast and will have no effect on the vote.”.

b. Approved under the standard stated in the filing — “Abstentions will not count as votes cast and will have no effect on the vote.”.

c. Approved under the standard stated in the filing — “Abstentions will not count as votes cast and will have no effect on the vote.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	44 : 1
CEO total compensation	$4,887,318
Median employee compensation	$112,114

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Stephen D. Griffin	Director	2026-04-30	A	12,200	$12	$149,881	Common	Form 4 ↗
John B. Henneman, III	Director	2026-05-01	A	5,000	15	73,320	Common	Form 4 ↗
Stephen D. Griffin	Director	2026-06-03	D	12,840	0	0	Derivative, Class A Common	Form 4 ↗
Stephen D. Griffin	Director	2026-06-03	D	3,769	14	54,311	Common	Form 4 ↗
Stephen D. Griffin	Director	2026-06-03	A	12,840	—	—	Common	Form 4 ↗
Joseph H. Capper	Director	2026-06-18	A	10,402	0	0	Common	Form 4 ↗
Sheryl L. Conley	Director	2026-06-18	A	10,402	0	0	Common	Form 4 ↗
John B. Henneman, III	Director	2026-06-18	A	10,402	0	0	Common	Form 4 ↗
Stephen O. Richard	Director	2026-06-18	A	10,402	0	0	Common	Form 4 ↗
Gary P. Fischetti	Director	2026-06-18	A	10,402	0	0	Common	Form 4 ↗
Gary P. Fischetti	Director	2026-08-03	A	1,000	21	20,745	Common	Form 4 ↗
Gary P. Fischetti	Director	2026-08-04	A	1,000	20	20,315	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (59 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Cheryl Blanchard. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 64. As printed: 4,887,318. View filing ↗
Section 01, Stephen Griffin. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 64. As printed: 2,033,370. View filing ↗
Section 01, David Colleran. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 64. As printed: 1,614,205. View filing ↗
Section 01, Anne Nunes. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 64. As printed: 946,571. View filing ↗
Section 01, Ian McLeod. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 64. As printed: 765,544. View filing ↗
Section 03, Ian McLeod RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
Section 03, Anne Nunes RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
Section 03, Cheryl Blanchard RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
Section 03, David Colleran RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
Section 03, Stephen Griffin RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A. Section “CEO Pay Ratio”. As printed: 44 : 1.
Section 08, John B. Henneman, III. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 267,497. View filing ↗
Section 08, Susan L. N. Vogt. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 229,997. View filing ↗
Section 08, Stephen O. Richard. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 229,997. View filing ↗
Section 08, Sheryl L. Conley. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 224,997. View filing ↗
Section 08, William R. Jellison. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 224,997. View filing ↗
Section 08, Joseph H. Capper. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 222,497. View filing ↗
Section 08, Glenn R. Larsen, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 212,497. View filing ↗
Section 08, Gary P. Fischetti. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 212,497. View filing ↗
Section 08, Cheryl R. Blanchard, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, Stephen D. Griffin. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Stephen D. Griffin 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John B. Henneman, III 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen D. Griffin 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen D. Griffin 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen D. Griffin 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph H. Capper 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sheryl L. Conley 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John B. Henneman, III 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen O. Richard 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary P. Fischetti 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary P. Fischetti 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary P. Fischetti 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-06-23. Item 5.07 · say-on-pay result. As reported: 88.32% (votes for as printed: 8,268,676). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-24. Item 5.07 · say-on-pay result. As reported: 76.8% (votes for as printed: 8,374,076). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-07-11. Item 5.07 · say-on-pay result. As reported: 98.84% (votes for as printed: 11,020,273). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 625,000 + equity 1,199,976 + all other 0 = 1,824,976, summed across the director compensation table rows.
Vericel Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. View filing ↗
AxoGen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in AxoGen, Inc.'s own proxy. As printed: 9,047,454. View filing ↗
Travere Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. View filing ↗
MiMedx Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in MiMedx Group, Inc.'s own proxy. As printed: 7,182,208. View filing ↗
Artivion, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. View filing ↗
Organogenesis Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Organogenesis Holdings Inc.'s own proxy. As printed: 6,811,754. View filing ↗
Akebia Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Akebia Therapeutics, Inc.'s own proxy. As printed: 5,652,339. View filing ↗
Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
Avid Bioservices, Inc., Section 10b CEO total. DEF 14A, filed 2024-08-28. CEO total compensation as printed in Avid Bioservices, Inc.'s own proxy. As printed: 4,475,343. View filing ↗
Bioventus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Bioventus Inc.'s own proxy. As printed: 4,299,108. View filing ↗
Vanda Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals, Inc.'s own proxy. As printed: 3,851,468. View filing ↗
SurModics, Inc., Section 10b CEO total. DEF 14A, filed 2024-12-19. CEO total compensation as printed in SurModics, Inc.'s own proxy. As printed: 3,665,496. View filing ↗
Heron Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. View filing ↗
Karyopharm Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics, Inc.'s own proxy. As printed: 2,320,902. View filing ↗
MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
Anika Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Anika Therapeutics, Inc.'s own proxy. As printed: 2,033,370. View filing ↗
Collegium Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. View filing ↗
Section 10a, MiMedx Group, Inc. reciprocity. DEF 14A. MiMedx Group, Inc. names Anika Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, SurModics, Inc. reciprocity. DEF 14A. SurModics, Inc. names Anika Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Organogenesis Holdings Inc. reciprocity. DEF 14A. Organogenesis Holdings Inc. names Anika Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗